ANXA1 and intrahepatic cholangiocarcinoma: More importantly, we determined the impact of ANXA1 on GOT1-mediated glutamine metabolism and gained critical insights into the pathogenesis mechanisms underlying ICC, providing a basis for potential therapeutic targets.